Background and Objective: The congenital factor V deficiency, known as Owren's disease or parahemophilia is a rare autosomic recessive haemorrhagic disease of coagulation, identified for the first time in Norway in 1943. In Morocco, there is no national registry including cases of congenital coagulopathy. This study highlights the rarity of inherited factor V deficiency deficiency and the importance of coagulation testing in the diagnosis of condition.
Introduction
Factor V, known as Owren's disease or parahemophilia is a very rare inherited haemorrhagic disease of coagulation with an autosomic recessive transmission, identified for the first time in Norway in 1943 [1] . About one person in a million may be affected by this deficiency, it is asymptomatic among the heterozygous, and manifests itself among the homozygote by some mucocutaneous bleeding of variable intensity depending on families.
We conducted a retrospective analysis of all cases with factor V deficiency that were seen and followed up within a 21-year period at the University Hospital of Casablanca, a large Moroccan city with more than 3 million habitants.
Patients and Methods
Between January 1991 -December 2012 (no new case was noted), the medical records of patients with congenital factor V deficiency were followed up at University Hospital Center 'Ibn Rochd' in Casablanca and were carefully reviewed for clinical and laboratory features. The Ibn Rochd Center is one of the biggest university hospitals in Morocco and receives approximately 98000 patients per year.
We have gathered studied the different data (epidemiological, clinical, biological and therapeutic) and we have conducted a family survey in search of similar cases. The biological diagnosis of the deficit is based on an assessment of haemostasis with the exploration of prothrombin time (PT) test in the presence of neoplastin (Diagnostica stago type), partial thromboplastin time with activators (aPTT) test performed in the presence of cephalin (Organo type) and a specific measure for factor V by chronometric method with a deficient substrat in factor V and in the presence of thromboplastin [normal range of factor V:
The severity of the factor V deficiency is classified according to the level of the factor V deficiency. The deficit is severe if the factor V is ≤ 1%, moderate if the factor V is < 5% and minor if the factor V is V ≥ 5%.
Factor VIII is measured in all patients to eliminate a combined deficit.
Results
Twelve patients were included with a factor V deficit. Seven patients were followed for a hemorrhagic syndrome and five were diagnosed as part family survey. The average age of the patients was 16 with extremes of 1 to 40 years. The sex ratio was 2 with female predominance. Parental consanguinity of the first degree was found in three patients. In 7 patients followed in our unit; presenting signs of deficiency were: menorrhagia in 3 cases, epistaxis in 2 cases, purpuric lesions of lower limbs in 1 patient, circumcision bleeding in 1 case, a hematoma with hemarthrosis in 1 case, bleeding after tooth extraction in 1 case, intra-operative bleeding in 1 case and a chance discovery during a preoperative review in 1 case (Table 1) .
Of the five patient discovered in the family survey, one patient has a history of epistaxis. All patients had abnormal coagulation evaluation with lengthening of PT and aPTT. The activity of factor V was greater than or equal to 5% in 8 patients, less than 5% in 4 patients. No associated deficit has been founded ( Table 2) . 
Discussion
Factor V or proaccelerin is blood clotting protein that acts as a cofactor, accelerating the conversion of prothrombin into thrombin. It belongs to the common pathology, and it is at the centre of regulatory mechanisms of coagulation, allowing the reaction at the site to occur at the site of vascular injury.
The gene responsible for synthesis of factor V is located on the 1q23 locus. These are mutations at this locus that are responsible of the deficit. They affect the two chromosome pairs in the homozygous symptomatic forms [2] .
The congenital deficiency of Factor V is rare, affecting 1/1000000 individuals in the general population. However, its prevalence may be underestimated because mild cases are often overlooked [1, 3, 4] . This deficiency is due to an autonomic recessive transmission, it is more common in countries where consanguineous marriages are common, which is the case in our country. Until now only 200 cases have been reported [3, 5] .
Congenital factor V deficiency type I is defined by a reduction FV activity and antigen. For type II, the deficit is qualitative and is characterized by low of stability of activated factor V with normal antigen level [6, 7] .
Biological factor V deficiency is characterized by clinical phenotype and genotype heterogeneity [1, 3] .
Factor V deficiency is usually asymptomatic in heterozygote or homozygote patient, but in some patients it is manifested by mucosal or cutaneous bleeding of variable intensity [3, 9] .
A large Study of 35 Iranian patients reported mucocutaneous bleeding in 57%, bleeding of the oral cavity in 57%, heavy or prolonged menstrual bleeding in 50%, post-traumatic bleeding and peri-operating in 43% of muscle hematomas in 29%, hemarthrosis in 26%.
Intracranial or gastrointestinal tract hemorrhages are rare (6%) and are limited to patients with undetectable FV; they occur mainly in the perinatal period [3, 8] .
The results of our study are consistent with those reported, despite a very small number of patients in our series, with mucosal bleeding found in 2 of 7 patients and menorrhagia in 3 out of 6 female patients.
In most cases of severe FV deficiency hemorrhagic signs appear at birth or in infancy, but some remain virtually asymptomatic until late in life and may be discovered incidentally after a routine coagulation evaluation . [4, 9] . Heterozygotes are usually asymptomatic or have minor bleeding.
The biological diagnosis is suggested in a prolonged PT and aPTT. It is confirmed by the analytical determination of factors II, VII, X and V, confirming the isolated deficiency of clotting activity of factor V. There is no correlation between FV and intensity of clinical signs, in fact there is no parallelism between the degree of deficit and the severity or frequency of symptoms [3, 7] .
The treatment or prevention of first-line intraoperative haemorrhage involves transfusion of fresh frozen plasma (FFP) because there is no specific FV concentrate [3, 6, 7] .
The aim of treatment by FFP is maintain of the FV level above 20%. The half-life of FV is 12-36 h, a daily transfusion of 15-20 ml/kg FFP is sufficient to obtain the therapeutic level. The frequency and dose must be adjusted on a case by case basis [3, 10] . For less severe mucocutaneous bleeding, the use of an antifibrinolytic such as aminocaproic acid may be sufficient.
In conclusion, Factor V deficiency is a rare bleeding disorder affecting both men and women, and it may cause in some cases very severe bleeding. Its diagnosis is easily made by standard coagulation of evaluation of PT, aPTT and factor V activity level. Early diagnosis is essential for adequate replacement therapy to be instituted if necessary. Given the small numbers of patients with factor V deficiency, is essential to continue collaborative efforts with international registries to expand our knowledge of this and other rare coagulation disorders.
